US 2019/0262453 Al  31  Aug. 29, 2019  13.  The composition of claim  1,  wherein said composition  further comprises one or more of a non-ionic surfactant, a  niosome, a polymer, a protein, and a carbohydrate.  14.  The composition of claim  10,  wherein said lipid is  modified to comprise a targeting agent selected from the  group consisting of antibodies, mannose, folate, and trans› ferrin.  15-21.  (  canceled)  22.  A method of treating a disease in a subject, compris› ing:  23.  The method of claim  22,  wherein said administering  reduces or eliminates symptoms of said disease.  24.  The method of claim  22,  wherein said disease is an  inflammatory disease.  25.  The method of claim  24,  wherein said disease is acute  or chronic.  phylactic shock, immune complex disease, organ ischemia,  reperfusion injury, organ necrosis, hay fever, sepsis, septi› cemia, endotoxic shock, cachexia, hyperpyrexia, eosino› philic granuloma, granulomatosis, sarcoidosis, septic abor› tion,  epididymitis,  vaginitis,  prostatitis,  urethritis,  bronchitis, emphysema, rhinitis, pneumonitits, pneumoult› ramicroscopic silicovolcanoconiosis, alvealitis, bronchioli› tis, pharyngitis, pleurisy, sinusitis, influenza, respiratory  syncytial virus infection, HIV infection, hepatitis B virus  infection, hepatitis C virus infection, herpes virus infection  disseminated  bacteremia,  Dengue  fever,  candidiasis,  malaria, filariasis, amebiasis, hydatidcysts, bums, dermati› tis, dermatomyositis, sunburn, urticaria, Warts, Wheals,  vasulitis, angiitis, endocarditis, arteritis, atherosclerosis,  thrombophlebitis,  pericarditis,  myocarditis,  myocardial  ischemia, periarteritis nodosa, rheumatic fever, Alzheimer’s  disease, coeliac disease, congestive heart failure, adult respi› ratory distress syndrome, meningitis, encephalitis, multiple  sclerosis, cerebral infarction, cerebral embolism, Guillame› Barre syndrome, neuritis, neuralgia, spinal cord injury,  paralysis, uveitis, arthritides, arthralgias, osteomyelitis, fas› ciitis, Paget’s disease, gout, periodontal disease, rheumatoid  arthritis, synovitis, myasthenia gravis, thyroiditis, systemic  lupus erythematosis, Goodpasture’s syndrome, Behcet’s  syndrome, allograft rejection, graft-versus-host disease,  Type I diabetes, Type II diabetes, ankylosing spondylitis,  Berger’s disease, Reiter’s syndrome, Hodgkin’s disease,  ileus, hypertension, irritable bowel syndrome, myocardial  infarction, sleeplessness, anxiety, local inflammation, and  stent thrombosis.  26.  The method of claim  22,  wherein said disease is  selected from the group consisting of asthma, bronchiolitis,  bronchiolitis obliterans, chronic obstructive pulmonary dis› ease (COPD), bronchitis, emphysema, hypersensitivity  pneumonitis, idiopathic pulmonary fibrosis, pneumoconio› sis,  silicosis,  meningitis,  sepsis,  malaria,  rheumatoid  osteoarthritis, psoriasis, acute respiratory disease syndrome,  inflammatory bowel disease, multiple sclerosis, joint inflam› mation, reactive arthritis, hay fever, atherosclerosis, rheu› matoid arthritis, bursitis, gouty arthritis, osteoarthritis, poly› myalgia rheumatic arthritis,  septic arthritis,  infectious  arthritis, asthma, autoimmune diseases, chronic inflamma› tion,  chronic  prostatitis,  glomerulonephritis,  nephritis,  inflammatory bowel diseases, pelvic inflammatory disease,  reperfusion injury, transplant rejection, vasculitis, myocardi› tis, colitis, appendicitis, peptic ulcer, gastric ulcer, duodenal  ulcer, peritonitis, pancreatitis, ulcerative colitis, seudomem› branous colitis, acute colitis, ischemic colitis diverticulitis  epiglottitis, achalasia, cholangitis, cholecystitits, hepatitis:  Crohn’s disease, enteritis, Whipple’s disease, allergy, ana- 27.  The method of claim  26,  wherein said disease is  caused by infection by a microorganism selected from the  group consisting of  Staphylococcus aureus, Streptococcus,  Streptococcus pneumonia, Neisseria gonorrhoeae, Myca› bacterium tuberculosis, Borrelia burgdorferi,  and  Haemo› philus influenza.  28-31.  (canceled)  *  *  *  *  *  administering the composition of claim  1  to a subject  diagnosed with a disease. 